John Wilding
Impact in
- Endocrinology, Diabetes and Metabolism top 0.01%
- Diabetes Treatment and Management
- Diabetes Management and Research
- Endocrine and Autonomic Systems top 0.05%
- Regulation of Appetite and Obesity
Papers in
-
- Diabetes Treatment and Management 169
- Physiology 86
- Diet and metabolism studies 43
- Adipose Tissue and Metabolism 17
- Obstructive Sleep Apnea Research 16
- Co-authors
- Ofri Mosenzon (40 shared papers)Lawrence A. Leiter (43 shared papers)Deepak L. Bhatt (44 shared papers)Marc S. Sabatine (42 shared papers)Darren K. McGuire (40 shared papers)Avivit Cahn (36 shared papers)Marc P. Bonaca (10 shared papers)Thomas A. Zelniker (16 shared papers)
- Journals
- Diabetes Obesity and Metabolism (33 papers)British Journal of Psychology (14 papers)Diabetes (13 papers)Diabetic Medicine (13 papers)Diabetes Therapy (12 papers)
- Partner nations
- United KingdomUnited StatesCanada
In The Last Decade
John Wilding
455 papers receiving 36.7k citations
John Wilding's Hit Papers
Peers
Comparison fields: 5 of 200
- Endocrinology, Diabetes and Metabolism 18.1k
- Endocrine and Autonomic Systems 3.8k
- Pharmacology 4.9k
- Physiology 6.8k
- Pharmacy 741
Countries citing papers authored by John Wilding
This map shows the geographic impact of John Wilding's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by John Wilding with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites John Wilding more than expected).
Fields of papers citing papers by John Wilding
This network shows the impact of papers produced by John Wilding. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by John Wilding. The network helps show where John Wilding may publish in the future.
Co-authors
The 25 scholars most cited alongside John Wilding, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 469 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes Hit paper breakdown → | 2018 | 4456 |
| 2 | Once-Weekly Semaglutide in Adults with Overweight or Obesity Hit paper breakdown → | 2021 | 2792 |
| 3 | SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials Hit paper breakdown → | 2018 | 1962 |
| 4 | A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management Hit paper breakdown → | 2015 | 1884 |
| 5 | A role for glucagon-like peptide-1 in the central regulation of feeding Hit paper breakdown → | 1996 | 1630 |
| 6 | Obesity: a chronic relapsing progressive disease process. A position statement of the World Obesity Federation Hit paper breakdown → | 2017 | 1068 |
| 7 | Management of obesity Hit paper breakdown → | 2016 | 769 |
| 8 | Effects of Dapagliflozin on Body Weight, Total Fat Mass, and Regional Adipose Tissue Distribution in Patients with Type 2 Diabetes Mellitus with Inadequate Glycemic Control on Metformin Hit paper breakdown → | 2012 | 713 |
| 9 | Lower Risk of Heart Failure and Death in Patients Initiated on Sodium-Glucose Cotransporter-2 Inhibitors Versus Other Glucose-Lowering Drugs Hit paper breakdown → | 2017 | 623 |
| 10 | Efficacy and safety of semaglutide compared with liraglutide and placebo for weight loss in patients with obesity: a randomised, double-blind, placebo and active controlled, dose-ranging, phase 2 trial Hit paper breakdown → | 2018 | 606 |
| 11 | Weight regain and cardiometabolic effects after withdrawal of semaglutide: The Hit paper breakdown → | 2022 | 585 |
| 12 | Comparison of the Effects of Glucagon-Like Peptide Receptor Agonists and Sodium-Glucose Cotransporter 2 Inhibitors for Prevention of Major Adverse Cardiovascular and Renal Outcomes in Type 2 Diabetes Mellitus Hit paper breakdown → | 2019 | 565 |
| 13 | Differentiation of Diabetes by Pathophysiology, Natural History, and Prognosis Hit paper breakdown → | 2016 | 546 |
| 14 | 2002 | 433 | |
| 15 | Dapagliflozin maintains glycaemic control while reducing weight and body fat mass over 2 years in patients with type 2 diabetes mellitus inadequately controlled on metformin Hit paper breakdown → | 2013 | 394 |
| 16 | Long-Term Efficacy of Dapagliflozin in Patients With Type 2 Diabetes Mellitus Receiving High Doses of Insulin Hit paper breakdown → | 2012 | 393 |
| 17 | SGLT2 inhibitors and GLP-1 receptor agonists: established and emerging indications Hit paper breakdown → | 2021 | 384 |
| 18 | 2012 | 361 | |
| 19 | Economic impacts of overweight and obesity: current and future estimates for 161 countries Hit paper breakdown → | 2022 | 338 |
| 20 | Effect of Dapagliflozin on Atrial Fibrillation in Patients With Type 2 Diabetes Mellitus Hit paper breakdown → | 2020 | 333 |
About John Wilding
John Wilding is a scholar working on Endocrinology, Diabetes and Metabolism, Physiology, Molecular Biology, Pharmacology and Endocrine and Autonomic Systems, having authored 469 papers that have together received 38.0k indexed citations. Recurring topics across this work include Diabetes Treatment and Management (169 papers), Pharmacology and Obesity Treatment (67 papers), Regulation of Appetite and Obesity (56 papers), Metabolism, Diabetes, and Cancer (52 papers), Diet and metabolism studies (43 papers), Neuropeptides and Animal Physiology (20 papers), Adipose Tissue and Metabolism (17 papers) and Obstructive Sleep Apnea Research (16 papers). The work is most often cited by research in Endocrinology, Diabetes and Metabolism (18.1k citations), Endocrine and Autonomic Systems (3.8k citations), Pharmacology (4.9k citations), Physiology (6.8k citations) and Pharmacy (741 citations). John Wilding has collaborated with scholars based in United Kingdom, United States and Canada. Frequent co-authors include Ofri Mosenzon, Lawrence A. Leiter, Deepak L. Bhatt, Marc S. Sabatine, Darren K. McGuire, Avivit Cahn, Marc P. Bonaca, Thomas A. Zelniker, Eri Kato and Stephen D. Wiviott. Their work appears in journals such as Diabetes Obesity and Metabolism, British Journal of Psychology, Diabetes, Diabetic Medicine and Diabetes Therapy.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.